课题基金 / 基金详情

项目摘要

项目成果

Michael Emerman的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract The human immunodeficiency virus (HIV) is opposed by host cell factors, called “restriction factors” with the potential to significantly control viral replication and affect disease progression and viral transmission. Our hypothesis is that the critical balance between the activity of restriction factors and the ability of the virus to antagonize or evade these factors plays in important role in HIV evolution, and ultimately, our ability to cure this infection. While some restriction factors are very active against HIV, others work poorly in humans or are polymorphic in the human population with both active and inactive versions. In the APOBEC3 locus of restriction factors, APOBEC3H stands out because some humans make active versions of this protein, while others do not, and a newly discovered polymorphism in APOBEC3C has increased activity in a subset of humans. Antagonism of all of the APOBEC3 proteins is dependent on the activity of the HIV-1 Vif protein which itself is polymorphic and must attack multiple host proteins at once. We will continue our studies on the interactions of restriction factors against HIV by determining the consequences of virus going from individuals with differing repertoires of APOBEC3 proteins. We will use an already established discordant couples cohort to understand the evolution and function of Vif proteins when virus is transmitted from an individual with one APOBEC3H genotype to a person with a different APOBEC3H genotype. In parallel, we will also exploit the natural infection of African Green Monkeys (AGMs) subspecies with divergent SIVs to understand how polymorphism in the APOBEC3 locus affects the evolution of the lentivirus-host relationship. In addition, we will determine the importance and mechanism of a gain-of-function polymorphism in APOBEC3C. We will further study the evolutional potential of Vif-APOBEC3 interactions by determining the steps needed for SIV Vif proteins to adapt to antagonize the human APOBEC3 repertoire. Finally, we have initiated an innovative and flexible CRISPR/Cas9 screen for novel restriction factors that will provide further insights into the interactions between HIV and its host that affect virus replication. Overall, the goal of this proposal is to understand how the evolution and function of these restriction factors impacts HIV replication in humans.
期刊论文(47)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.chom.2012.01.004
发表时间: 2012-02-16
期刊: Cell host & microbe
影响因子: 30.3
作者: [Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M]
通讯作者: Emerman M
HIV-1 Vpr does not inhibit CTL-mediated apoptosis of HIV-1 infected cells.
HIV-1 Vpr 不会抑制 CTL 介导的 HIV-1 感染细胞凋亡。
DOI: 10.1006/viro.2001.1294
发表时间: 2002
期刊: Virology.
影响因子: --
作者: [Lewinsohn,DeborahA, Lines,Rebecca, Lewinsohn,DavidM, Riddell,StanleyR, Greenberg,PhilipD, Emerman,Michael, Bartz,StevenR]
通讯作者: Bartz,StevenR
DOI: 10.1186/1742-4690-9-55
发表时间: 2012-06-26
期刊: Retrovirology
影响因子: 3.3
作者: [Lim ES, Wu LI, Malik HS, Emerman M]
通讯作者: Emerman M
DOI: 10.1371/journal.pgen.1004761
发表时间: 2014-11
期刊: PLoS genetics
影响因子: 4.5
作者: [Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, Brown WL, Reilly C, Emerman M, Harris RS]
通讯作者: Harris RS
共 19 条
    HIV-CRISPR: A novel approach to the comprehensive discovery of HIV latency factors
    • 批准号:
      10642658
    • 项目类别:
    • 资助金额:
      $88.0万
    • 财政年份:
      2020
    • 负责人:
      Michael Emerman
    • 依托单位:
    HIV-CRISPR: A novel approach to the comprehensive discovery of HIV latency factors
    • 批准号:
      10371192
    • 项目类别:
    • 资助金额:
      $88.0万
    • 财政年份:
      2020
    • 负责人:
      Michael Emerman
    • 依托单位:
    The Evolution of Vpr/Vpx Function in Primate Lentiviruses
    The Evolution of Vpr/Vpx Function in Primate Lentiviruses
    海外基金